InnovAge (INNV) Q1 2027 Earnings Call Transcript

InnovAge (INNV) reported Q1 2027 revenue of $264.8M, up 12.1% YoY, and adjusted EBITDA of $31.3M, up 75%. The company cited growth in census and profitability, investments in clinical and operational capabilities, and plans for expansion. Management discussed the impact of the V28 Medicare risk adjustment model, noting differences between PACE and Medicare Advantage.

Original reporting
Published Nov 4, 2026, 3:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 3:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
InnovAge (INNV) Q1 2027 Earnings Call Transcript — source image
Decision brief

The 30-second read

$INNVNeutralMed
01

Why it matters

The earnings datapoints (revenue growth, adjusted EBITDA growth, and census increase) support the bull case for operating leverage, while the V28 explanation highlights potential reimbursement pressure and how PACE’s frailty factor and participant mix could mitigate or alter the impact.

02

Market read

Traders can update positioning based on fresh quarterly performance and the company’s stated view on how V28 may affect PACE reimbursement and margins.

03

What to watch

The transcript excerpt ends mid-sentence on V28; traders may need the full call for any quantified sensitivity, guidance, or management commentary on timing of reimbursement impacts and mitigation actions.

Relevance 7/10Novelty 6/10Timing: today’s earnings-call transcript, with V28 reimbursement discussion likely to drive near-term positioning

Background

InnovAge is a PACE provider, and the call addresses its Q1 fiscal 2027 performance and the industry transition to the V28 Medicare risk adjustment model.

Company-level read

Ticker impact

$INNVNeutralMedium confidence
Context

InnovAge reports Q1 fiscal 2027 results and discusses its InnovAge 3.0 strategy plus how V28 Medicare risk adjustment may affect PACE reimbursement.

Expected impact

Shares may see two-sided trading as the market weighs strong Q1 momentum against uncertainty around V28 reimbursement pressure and how PACE’s frailty factor offsets diagnosis-weight changes.

Evidence & confidence

The transcript provides fresh quarterly datapoints (revenue, adjusted EBITDA, census) and a detailed framework for V28 impacts, which can shift expectations for future margins and utilization.

Market effects

PACE providers and Medicare Advantage-adjacent models may see renewed focus on how risk-adjustment methodology changes flow through to margins.

no specific regional catalyst beyond multi-state operating footprint mentioned.

limited, as the story is US Medicare reimbursement mechanics and a single-company earnings call.

Counterpoint

The V28 discussion may not eliminate risk; investors could discount management’s qualitative differences and still price in margin compression if utilization or coding patterns shift.

Key entities

  • InnovAge

    PACE provider reporting Q1 fiscal 2027 results and outlining InnovAge 3.0 growth priorities plus V28 reimbursement implications.

  • V28 Medicare risk adjustment model

    Medicare risk scoring methodology change that can alter diagnosis weights and reimbursement for Medicare Advantage and related models.

Related articles

$INNVMed

InnovAge settles DOJ civil claims for $37 million

InnovAge Holding Corp. (INNV) settled civil claims with the DOJ for $37 million, covering alleged conduct from 2016 to 2022. The company did not admit wrongdoing. InnovAge provides senior healthcare programs and has invested in compliance and operations. As of September 2026, it served 8,420 participants across 20 centers in six states.

$INNVMed

What InnovAge (INNV) Said on Its Q1 Earnings Call

InnovAge (INNV) reported Q1 cost of care rose 12.7% to $85.5M, citing growth and higher expenses. The company is investing in care teams and technology to reduce costs. InnovAge reaffirmed its fiscal 2027 guidance, expecting revenue of $1.05B-$1.085B and adjusted EBITDA of $105M-$115M. Medicare rates are expected to increase 1.5%-2% from Jan 1, 2024.

$INNVHigh

INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026

InnovAge Holding Corp. (INNV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2026 DENVER, CO., November 3, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare